Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
about
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomasRole of "old" pharmacological agents in the treatment of Cushing's syndromeTemozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Invasive adenoma and pituitary carcinoma: a SEER database analysisTemozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.Treatment Options in Cushing's Disease.Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary TumorsO-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysisPrognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up.Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour groupTemozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.Temozolomide in the management of dopamine agonist-resistant prolactinomas.Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.Temozolomide in aggressive pituitary adenomas and carcinomas.Clinicopathological correlations in pituitary adenomas.Recent developments in drug therapy for Cushing's disease.Aggressive pituitary adenomas--diagnosis and emerging treatments.In search of a prognostic classification of endocrine pituitary tumors.Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.Cushing's syndrome: an update on current pharmacotherapy and future directions.Optimal management of non-functioning pituitary adenomas.Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and Review of the Literature.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.Therapeutic Strategies for the Treatment of Severe Cushing's Syndrome.The safety of treatments for prolactinomas.Is there a role for early chemotherapy in the management of pituitary adenomas?How effective is temozolomide for treating pituitary tumours and when should it be used?Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reportsCurrently used and investigational drugs for Cushing´s disease.Risk factors and the prognosis of sexual dysfunction in male patients with pituitary adenomas: a multivariate analysis.A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment.A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology.A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.Management of NFAs: medical treatment.MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Anti-VEGF therapy in pituitary carcinoma.Long-lasting complete remission after therapy with temozolomide in two patients with macrocorticotropinoma causing Cushing's disease.
P2860
Q26772167-0894BA9D-35FE-45B7-83BA-51665EC325F5Q28067685-52714D59-E73B-47A0-936C-91003F7BB110Q33427688-19131796-AD00-4E43-8872-7CEE9C241756Q33914197-285181D1-AFF6-4C32-AAC4-78F8E782B48DQ35067759-4272357D-E218-449E-95B8-905875BDEC21Q35708559-C4A3886E-7E36-4F43-81C3-411CE19C630DQ35740882-0BB97B8D-BC0F-42BA-84D6-8558D3FA1D1EQ35785924-A419A9F1-563D-40FF-BF1E-8430DB206FF3Q35932525-9BCDE367-F9D8-497C-B1EA-A4B0B6935F23Q36268061-28883D8B-FF53-4133-8934-A1EC8AE1B220Q37222927-2853A6A1-5705-4007-A50E-905FD57B1958Q37629658-EEF40135-DEC2-4AA1-8C79-7D56C92D1C65Q37955091-DDB0C8F2-2754-4365-B058-CE106827E031Q37988909-28100B1C-D5AF-4A70-840E-0455C412E682Q37992191-A1C615E9-B155-4181-8404-9660FE03968CQ38010032-7618301E-7F9E-4CB9-9F74-51C5DC525AF3Q38018648-85BB947A-5F09-444E-A4A5-AECEF973A66EQ38112082-00A25221-605E-4D78-9588-EC3999B50B34Q38211375-5DEB05A4-4F92-4572-9194-C20438A689E2Q38212659-5B8E7FC4-BDF3-410A-A2BE-CA6E85E529A6Q38365297-3F465180-9CDE-4F3F-BE1C-01BAB7045367Q38541695-02EB8E50-EE4B-44BA-A881-33EE55BDA4A1Q38547977-9FE6DF1F-2CF3-43F5-BA8C-8F5F62689A0DQ38556703-4FB3FE10-6905-4783-810A-B1039A19393CQ38650974-CF37DBA1-4E6F-47C0-81B4-71CEB2841A3CQ38718807-DD57D918-CC30-4076-968A-632E6BFE2F93Q38726058-A02EBCF8-DBF8-4708-BBCF-A3D357865FB7Q38815400-442BFCE5-A586-417C-AA81-8EE0F496A1EFQ38825694-92E4BA3F-A283-48B5-BC91-FFDFC0F9E798Q38934576-8FA86631-AF76-49DD-A7FE-CBB40AB0CACAQ39022297-FC6C28F0-6E9F-4602-BF55-7EB457B42427Q39151286-0EDB7B1F-BDA4-4EF4-BABB-C3AAB120A256Q42002190-AF54FF2E-70A4-4F9C-8661-ACE79104444EQ42374890-535FCE26-BA15-4586-8764-5883FC08714CQ46411571-BB73976B-7CA6-4581-A096-332ABAAF497CQ47161911-76AC1C13-72F2-41D6-A7A4-4722D03E96B9Q47726143-2D6A696B-7DC5-4158-B72B-10C105E34D3DQ49979233-5BE46357-02DB-4E48-AC98-A0C66AAFFD6EQ53202606-9F9DAA3B-378E-4790-85E7-114981B34D42Q53638299-E46D647E-B683-48AC-8BFB-64ADA6AAFF2F
P2860
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@en
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@nl
type
label
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@en
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@nl
prefLabel
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@en
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@nl
P2093
P2860
P1476
Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
@en
P2093
Ann I McCormack
Ashley B Grossman
John A H Wass
P2860
P304
P356
10.1111/J.1365-2362.2011.02520.X
P577
2011-04-18T00:00:00Z